Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TBC1D26 antisense RNA 1 (TBC1D26-AS1, also known as LOC105371559) is a human long non-coding RNA (lncRNA) gene transcribed antisense to the TBC1D26 locus[4][5][6]. Classified as a non-coding RNA, specifically an antisense lncRNA, it is presumed to play a regulatory role at the RNA level, modulating gene expression through epigenetic and post-transcriptional mechanisms, as is characteristic for this class of molecules[3][4][5]. While many antisense lncRNAs are implicated in processes such as chromatin modification and mRNA stability regulation, there is currently no direct evidence that TBC1D26-AS1 acts as a receptor, enzyme, or therapeutic target, nor are there reports of disease associations, interacting drugs, or biomarker use for this molecule[4][5][6]. Most references to TBC1D26-AS1 are found in gene databases, and no specific biological or pathogenic role has been firmly established in the published literature as of this date[4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TBC1D26 antisense RNA 1 (TBC1D26-AS1).